Use of methotrexate in patients with scleroderma and mixed connective tissue disease.
Systemic sclerosis (scleroderma, SSc) and mixed connective tissue disease (MCTD) are chronic autoimmune diseases characterised by a broad spectrum of clinical manifestations including different forms of musculoskeletal involvement, skin and vascular changes, as well as internal organ complications. Clinical course and outcomes might vary from mild forms with good clinical prognosis to severe rapidly progressive life-threatening diseases. At present, immunosuppressive therapies are considered a cornerstone in the treatment of MCTD, and are frequently used in clinical practice in SSc despite limited evidence from clinical trials. The aim of the present review is to discuss available data concerning efficacy of methotrexate therapy in SSc and MCTD.
Department of Rheumatology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland.
O
O
Kowal-Bielecka
O
O
Distler
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008727:Methotrexate / Q000627:therapeutic use*; D008947:Mixed Connective Tissue Disease / Q000188:drug therapy*; D012595:Scleroderma, Systemic / Q000188:drug therapy*; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents; D008727:Methotrexate